NYMC Faculty Publications
Hyperlipidemia in Children and Adolescents
Author Type(s)
Resident/Fellow, Faculty
DOI
10.1097/CRD.0000000000000465
Journal Title
Cardiology in Review
First Page
330
Last Page
335
Document Type
Article
Publication Date
11-1-2023
Department
Medicine
Abstract
While coronary artery disease (CAD) is thought to be a disease of adulthood, atherosclerosis can originate in childhood and adolescence. There is a paucity of randomized controlled treatment trials regarding dyslipidemia among the younger population. However, it is apparent that childhood dyslipidemia is associated with an earlier onset of CAD. Most recent guidelines by the American College of Cardiology (ACC) and American Heart Association (AHA) focus on lifestyle modification and lifetime risk of atherosclerotic disease, as well as adequate screening measures. Genetic factors, environmental contributors such as pollution, obesity linked to poor nutrition, and sedentary lifestyles are shown to be associated with increased lipid levels and early CAD among children and adolescents. Familial hyperlipidemia is one of the most prevalent genetic diseases and can affect 1 in 250 individuals. A multimodal treatment plan is most effective for children and adolescents with dyslipidemia including lifestyle changes (a modified diet and moderate physical activity) and pharmacologic intervention. The mainstay of pharmacologic treatment for childhood dyslipidemia is similar to that of adults. Statins are the most widely used medications. Newer medications have proven integral in treatment for genetic dyslipidemias including evolocumab and evinacumab.
Recommended Citation
Michaud, L., Sharedalal, P., Seplowe, M., Rosenzveig, A., Frishman, W. H., & Aronow, W. S. (2023). Hyperlipidemia in Children and Adolescents. Cardiology in Review, 31 (6), 330-335. https://doi.org/10.1097/CRD.0000000000000465